C5AR1 and Sepsis: The study disclosed that subjects displaying severe sepsis and septic shock upon receiving vilobelimab treatment selectively neutralized C5a in a dose-dependent manner exclusive of interference with the normal formation of the membrane attack complex (MAC) nor safety issue.